Skip to content
Search

Latest Stories

PSNC share tips for pharmacy contractors to reduce HRT SSP endorsement errors

The Pharmaceutical Services Negotiating Committee (PSNC) has advised the pharmacy contractors to check that their PMR systems supports correct and complete SSP endorsement.

Several tips has been shared by the PSNC with pharmacy contractors after NHSBSA received several electronic EPS SSP claims which did not meet the requirements for a valid SSP between 1 April 2022 and 31 May 2022.


PSNC has been working with NHS Business Services Authority (NHSBSA) to understand whether claims for HRT SSPs are being submitted correctly and in accordance with the specific supporting guidance for each SSP.

The reasons for incorrect/invalid SSP claims were due to:

  1. Reduced quantity not endorsed – for SSPs that require a reduced quantity to be endorsed, often the endorsed quantity matched the prescribed quantity. Majority of invalid SSP claims were due to this reason.
  2. Incorrect item endorsed – for SSPs that require substitution to an alternative product, the endorsed item was almost always the same as original prescribed item.
  3. Claims made against items without an active SSP – SSP endorsed against items for which a valid SSP did not exist.
  4. Claims for supplies made in accordance with an expired SSP:

    A. No active SSP in place at the time of supply – i.e., SSP claimed for items on prescriptions issued after SSP expired.

    B. Alternative item correctly supplied during the period of SSP validity, but Dispense Notification message submitted after the period of SSP validity.

    C. Alternative item correctly supplied during the period of SSP validity and the Dispense Notification message submitted during the period of SSP validity but the EREM or Claim Notification message submitted after the 3-month claiming window.5. Invalid or incorrect SSP reference number endorsed – For example SSP 000, SSP (missing reference number), SSP 028 (incorrect number), SSP 28 (two instead of three digits).

“For any invalid SSP claims, contractors will continue to receive the usual dispensing fee but will not receive any SSP fee (£5.35). Reimbursement for invalid SSP claims will also be in accordance with the prescribed product rather than the alternative product or quantity supplied in accordance with an SSP,” said PSNC.

“To ensure correct payments for SSP claims are received, contractors should follow the endorsement requirements outlined in the specific supporting guidance for each SSP,” suggested PSNC. “Contractors are strongly advised to check that their PMR systems supports correct and complete SSP endorsements. If there is any doubt on the correct use of the PMR system SSP functionality, contractors should contact their system supplier for further guidance.  Any suggestions about how system usability and functionality could be improved should also be fed back to the system supplier.”

PSNC’s Dispensing & Supply team have created easy to use flow charts to assist pharmacists in selecting the correct SSP for HRT medicines. These charts also remind contractors of the correct SSP endorsement requirements (with examples) and charge status to apply to the electronic messages before SSP claims are submitted for payment to the NHSBSA.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less